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Interferon beta-1a (IFN-b1a) is a cytokine therapy
used in the treatment of relapsing-remitting multiple
sclerosis. The most common adverse injection site
reactions include local erythema, pain, and indura-
tion.1 Other less frequently encountered reactions
include vascular thrombosis, ulceration, panniculitis,
and lipoatrophy.1 More recently, IFN-b rarely has
been noted to be associated with sclerosing skin
disorders including limited and diffuse systemic
sclerosis; however, the development of morphea
has not been reported.2 Here we describe a patient
with multiple sclerosis who had woody induration
clinically and histologically consistent with morphea
at the sites of subcutaneous IFN-b1a injections.
CASE REPORT
A 52-year-old African American woman with a
history of multiple sclerosis (MS) presented to the
dermatology clinic for evaluation of ‘‘firmness and
skin discoloration’’ at IFN-b1a injection sites. Five
years previously she began IFN-b1a therapy, and
approximately 6 months after initiation she noted
the gradual onset of firmness, skin depression, and
hyperpigmentation confined to the injection sites.
Over the last several years, she noted progression
and worsening of the induration and hyperpig-
mentation. Therefore IFN-b1a therapy was discon-
tinued, and she started taking oral dimethyl
fumarate approximately 1 year before presentation.
Interestingly, the woody induration continued to
progress despite cessation of interferon treatment.
Physical examination was remarkable for
depressed, indurated, bound-down, hyperpigment-
ed plaques involving her upper anterior thighs,
upper arms, and abdomen (Fig 1). The rest of the
cutaneous examination findings were unremarkable.
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and homogenization of collagen bundles extending
into the subcutaneous fat, paucity of adnexal struc-
tures, and a lymphoplasmacytic infiltrate in the deep
reticular dermis (Fig 2). The histologic features were
most consistent with the inflammatory stage of
morphea. Laboratory evaluations, including erythro-
cyte sedimentation rate, complete blood count, basic
metabolic panel, creatine kinase level, antinuclear
antibody, antitopoisomerase I, and anticentromere
antibody were within normal limits. The clinicopath-
ologic features were most consistent with morphea-
like skin changes occurring at the injection sites.
Currently, the treatment plan includes potent topical
steroids combined with topical calcitriol and the
initiation of systemic methotrexate therapy.DISCUSSION
Morphea is an inflammatory disorder character-
ized by fibrosis of the skin resulting in thickening of
the dermis and subcutaneous tissue, which may
extend to deeper underlying structures like fascia,
muscle, and bone. Morphea differs from systemic
sclerosis in that it does not involve internal organs,
Raynaud’s phenomenon, nailfold capillary changes,
or sclerodactyly.3 The pathogenesis is not clear but
likely is multifactorial. The currently accepted pro-
posed mechanism involves genetic factors and
environmental exposures resulting in small vesselJAAD Case Reports 2015;1:15-7.
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Fig 1. Depressed, indurated, bound-down hyperpigmented plaques involving anterior thighs
(A) and right hip (B).
Fig 2. A, Punch biopsy from the right thigh shows thickened collagen bundles extending into
the subcutaneous fat, paucity of adnexal structures, and a deep reticular lymphocytic infiltrate
(Hematoxylin-eosin stain; original magnification: 34). B, Higher magnification image shows
thickened collagen, lymphoplasmacytic infiltrate, and entrapment of the eccrine glands by
collagen (original magnification: 320).
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These factors lead to a disruption in the balance of
collagen production and destruction.3 Vascular
injury is believed to be the initial step leading to
increased expression of adhesion molecules, recruit-
ment of inflammatory cells, and an increase in the
production of profibrotic cytokines (transforming
growth factor beta), which promotes production and
decreases destruction of collagen.4 Numerous exog-
enous factors have been reported to play a role in
the development of morphea, including trauma,
injection, vaccination, infections, and radiation
therapy.3,5
Recently, there have been reports of sclerosing
skin disorder development secondary to various
biologic agents, including tumor necrosis factor
inhibitors and IFN-b.2,6 More recently, IFN-b1a was
reported to possibly trigger systemic sclerosis in
patients with multiple scleroris.2 The proposedmechanism involves an IFN-induced activation of
fibroblasts via T helper 2 (Th2) cytokines.2
Autoreactive T cells are thought to play an important
role in MS and systemic sclerosis (SSc), and antigen-
driven Th2 cell activation and upregulation of
interleukin 4 (IL-4) have been identified in active
SSc.7 This cytokine profile is also characteristic in MS
patients after initiating IFN-b treatment.8 Therefore,
skin sclerosis may develop subsequent to an IFN-
mediated Th2 upregulation.9
Our patient had cutaneous changes clinically and
histologically consistent with morphea at the injec-
tion sites a few months after initiation of IFN-b1a
therapy. Although pain, inflammation, and indura-
tion at injection sites are not uncommon, other, less
common reactions, such as panniculitis, lipoatrophy,
skin necrosis, ulceration, cutaneous vasculitis, lupus
erythematosuselike lesions, and SSc have been
reported.10Our patient presented onlywith localized
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sites and no other signs suggestive of limited or
diffuse systemic sclerosis. Hugle et al2 reported the
occurrence of sclerosing skin disorders in 12 patients
treated with IFN, of which, 8 had limited cutaneous
systemic sclerosis, 3 had diffuse cutaneous SSc, and 1
had antisynthetase syndrome. Eleven of these pa-
tients had Raynaud’s phenomenon and none had
morphea.2 With regard to patients injecting biologic
therapies, it is difficult to determine if this cascade of
events is caused by either vascular damage at injec-
tion sites or a treatment-induced alteration in the
cytokine profile. The clinical improvement of our
patient and reversibility of lesions in previously
reported cases6 on cessation of biologic therapy
supports the latter rather than the former. An initial
approach to the management would include discon-
tinuation of IFN therapy, the addition of topical
steroids or tacrolimus, ultraviolet phototherapy, or,
depending on the severity of the disease, the addition
of methotrexate with or without systemic steroids or
other immunosuppressive therapies.
The development of morphealike skin changes at
the sites of IFN injections in our patient could be
related to dysregulation of the Th1/Th2 cytokine
balance within the local microenvironment or sec-
ondary to trauma or a combination of both. Whereas
the development of morphea secondary to trauma
has been well appreciated, morphealike skin
changes occurring at the sites of IFN-b injections
have not been reported to the best of our knowl-
edge. It is possible that this adverse event is under-
reported, as biopsies in such cases are frequently not
performed.10
We report on a patient with MS who had woody
induration clinically and histologically consistentwith morphea at the sites of subcutaneous IFN-b1a
injections. The increasing use of biologic agents to
treat chronic medical conditions and the potential
interplay between these therapies and patients’
cytokine profiles necessitates awareness of all
possible cutaneous side effects.REFERENCES
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